The FreeDOM-DM1 study of the antisense agent PGN-EDODM1 has its clinical hold lifted by FDA.

Published Date: 19 Oct 2023

Treatment with PGN-EDODM produced a greater than 68 percent correction of downstream transcript missplicing events in preclinical data by reducing pathogenic nuclear foci by 54% per nucleus and freeing muscleblind-like splicing regulator 1.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot